← Back to guidelines
Endocrinology104 papers

Hypogonadotropic hypogonadism

Last edited: 4/14/2026

Overview

Hypogonadotropic hypogonadism (HH) is characterized by deficient production of sex hormones due to impaired gonadotropin secretion from the anterior pituitary, leading to delayed or absent puberty and infertility. It encompasses various forms including Kallmann syndrome (KS) with olfactory deficits and normosmic idiopathic HH 12.

Diagnosis

  • Olfactory Testing: Essential, especially in KS; use Sniffin' Sticks test and other olfactory assessments 1.
  • Endocrine Evaluation: Measure LH, FSH, and sex hormone levels to confirm HH 3.
  • Genetic Testing: Consider for normosmic idiopathic HH to identify underlying mutations affecting GnRH pathways 2.
  • Craniofacial Examination: Evaluate for non-olfactory abnormalities that may accompany KS 1.
  • Management

  • Testosterone Replacement: Initiate for development of secondary sexual characteristics in adolescents 3.
  • Induction of Spermatogenesis: Use pulsatile GnRH or gonadotropins (e.g., FSH, LH) to stimulate sperm production 3.
  • Monitoring: Regular follow-ups to assess long-term health, psychosocial function, and treatment efficacy 3.
  • Special Populations

  • Pediatrics: Early diagnosis crucial; include olfactory screening even with reported normal sense of smell 1.
  • Comorbidities: X-linked congenital adrenal hypoplasia may complicate HH management, requiring tailored GnRH dosing 4.
  • Key Recommendations

  • Perform olfactory screening tests and ENT examination in all cases of HH, even when anosmia is not reported, to facilitate early KS diagnosis 1 (Evidence: Strong).
  • Initiate testosterone therapy in young males with HH to promote pubertal development and secondary sexual characteristics 3 (Evidence: Moderate).
  • Consider genetic testing in normosmic idiopathic HH to guide understanding and potential future treatments 2 (Evidence: Moderate).
  • Use gonadotropins as an effective alternative to pulsatile GnRH for inducing spermatogenesis in HH patients 3 (Evidence: Moderate).
  • Regularly monitor patients with HH for long-term health outcomes and adjust therapy as necessary 3 (Evidence: Expert opinion).
  • References

    1 Dżaman K, Zborowska-Piskadło K, Pietniczka-Załęska M, Kantor I. Kallmann syndrome in pediatric otorhinolaryngology practice - Case report and literature review. International journal of pediatric otorhinolaryngology 2017. link 2 Fathi AK, Luo X. Normosmic idiopathic hypogonadotropic hypogonadism: update on the genetic background and future challenges. Journal of pediatric endocrinology & metabolism : JPEM 2013. link 3 Han TS, Bouloux PM. What is the optimal therapy for young males with hypogonadotropic hypogonadism?. Clinical endocrinology 2010. link 4 Kikuchi K, Kaji M, Momoi T, Mikawa H, Shigematsu Y, Sudo M. Failure to induce puberty in a man with X-linked congenital adrenal hypoplasia and hypogonadotropic hypogonadism by pulsatile administration of low-dose gonadotropin-releasing hormone. Acta endocrinologica 1987. link 5 Silverman AJ, Silverman R, Lehman MN, Witkin JW, Millar RP. Localization of a peptide sequence contained in the precursor to gonadotropin releasing hormone (GnRH). Brain research 1987. link90042-4)

    Original source

    1. [1]
      Kallmann syndrome in pediatric otorhinolaryngology practice - Case report and literature review.Dżaman K, Zborowska-Piskadło K, Pietniczka-Załęska M, Kantor I International journal of pediatric otorhinolaryngology (2017)
    2. [2]
      Normosmic idiopathic hypogonadotropic hypogonadism: update on the genetic background and future challenges.Fathi AK, Luo X Journal of pediatric endocrinology & metabolism : JPEM (2013)
    3. [3]
      What is the optimal therapy for young males with hypogonadotropic hypogonadism?Han TS, Bouloux PM Clinical endocrinology (2010)
    4. [4]
    5. [5]
      Localization of a peptide sequence contained in the precursor to gonadotropin releasing hormone (GnRH).Silverman AJ, Silverman R, Lehman MN, Witkin JW, Millar RP Brain research (1987)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG